N-Acetyl Semax Amidate + N-Acetyl Selank Amidate

1 Identity

Fixed-ratio two-component article: two all-L heptapeptides, each N-terminally acetylated and each C-terminally amidated, co-lyophilized. Both termini blocked on both components is the defining chemical fact. No metal center, no acyl chain beyond the terminal acetyl, no conjugate, no disulfide, no non-proteinogenic residue. Also indexed by its two component names; no trade title for this article has been identified, and the catalog names it by its components. The one adjacent observed title on the same shelf is "Adamax", recorded exactly as found. The name is the product'S only honest feature and is still incomplete: the two names state four modifications between them and no counterion, and the observed consumer channel abbreviates both back to the bare parent names on the vial.

Sequence

Per component, cross-referenced. N-Acetyl Semax Amidate Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2. N-Acetyl Selank Amidate Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2. Both carry two modifications the product names imply and most vendor descriptions omit. The corresponding free acids and the unacetylated parents are different articles and are specified impurities, not synonyms.

Molecular formula

Per component; a mixture has no combined formula and none is written. N-Acetyl Semax Amidate C39H54N10O10S free base; N-Acetyl Selank Amidate C35H60N12O9 free base. The Semax-family component carries the single Met1 sulfur and the Selank-family component carries none, so the isotope envelope assigns the two peaks independently of retention. An acetate counterion determination on an N-acetylated peptide requires a method distinguishing bound acetyl from free acetate ion, and that is stated rather than assumed.

Average mass

Per component, on IUPAC 2021 abridged conventional atomic weights: N-Acetyl Semax Amidate 854.981 Da; N-Acetyl Selank Amidate 792.940 Da. AT A nominal 10 mg + 10 mg fill, 20 mg total, the 1.00 : 1.00 mass ratio is a molar ratio of 1.000 : 1.078 - 11.69617 and 12.61129 micromol. Note the near-collision across the fork: N-Acetyl Semax free acid is 855.965 and N-Acetyl Selank free acid is 793.924, each within 1 Da of the intended component.

Monoisotopic mass

Per component. N-Acetyl Semax Amidate 854.3745 neutral, [M+H]+ 855.3818. N-Acetyl Selank Amidate 792.4606 neutral, [M+H]+ 793.4679. The critical separations are 0.9840 Da in both directions - each amidate against its own free acid. That is below unit resolution, so this article cannot be released on a nominal-mass instrument at all: the specification requires high-resolution accurate mass reported to four decimal places. The acetyl increment over each unmodified parent is exactly 42.0106.

Salt / variant note

(1) four molecules share the semax-side title: Semax 813.928; Semax amide 812.94; N-Acetyl Semax free acid 855.965; N-Acetyl Semax Amidate 854.981, this article's component and 0.984 Da below the free acid. "Adamax" is a further trade title on the same shelf. (2) three share the Selank-side title: Selank 751.887; N-Acetyl Selank free acid 793.924; N-Acetyl Selank Amidate 792.940. The N-Acetyl Selank single-article record carries the free acid as its catalog default while the observed market ships the amidate; this blend specifies the amidate explicitly rather than adopting one form silently. (3) ratio: no standard has been identified. (4) presentation: the observed consumer channel ships this family predominantly as solution sprays rather than lyophilized powder - a different article with different stability attributes, and not what this record specifies.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P1 — panel definitionfor both components, run per component and never once for the vial. The acetyl and the amide are terminal modifications rather than acylation in the P2 sense, so no P2 element is engaged and the union remains P1. What the modifications change is the identity test: N-terminal acetylation blocks Edman degradation entirely, so sequence confirmation here is MS/MS or nothing - a panel-level consequence rather than a footnote. Amino acid analysis gives the component ratio and no information at all about the modifications, because hydrolysis destroys both, and the certificate states that limitation rather than letting an AAA result stand as confirmation of a modified peptide

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists for the unmodified parents, is graded on their records and is cross-referenced rather than restated. Literature specific to the acetylated amidated forms is materially thinner than for the parents and is graded on the two component records accordingly. None of it is literature about this mixture. No published study of this fixed two-component combination has been identified.

4 Storage & specification

Storage

White to off-white co-lyophilized cake in Type I amber glass with a PTFE-lined closure, nitrogen headspace and in-pack desiccant; a non-sterile laboratory chemical carrying no sterility claim, supplied as powder in vials rather than as a spray solution or a unit-dose format. Store at -20 degrees C plus or minus 5 degrees C, desiccated, protected from light, the oxygen and light controls being set by the Met1 thioether on the Semax-family component with the reason stated on the label. Blocked termini shift the governing failure mode toward methionine oxidation and hydrolytic loss of the C-terminal amide. The label carries both component names in full with all four modifications, both quantities and the ratio, and never abbreviates back to the parent names.

Shelf life

Provisional 24 months at -20 degrees C plus or minus 5 degrees C, desiccated and light-protected, from QA release - the shorter of the two component intervals, provisional pending this company's own data. Stability-indicating attributes: per-component net content, the measured ratio, methionine sulfoxide, and free-acid growth at the 0.9840 Da offset on each component, which is the attribute this article exists to control and which no area-percent purity figure will reveal. Pulls at 0, 3, 6, 12, 18, 24 and 36 months, with a 6-month interim pull on each of the first three lots.